Search Results - "Stuart ASV"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    The collective voice of early phase COVID-19 vaccine trial participants: Insights for improving confidence in novel vaccines.

    Authors: Thomas TM Hodgson SH Emary K et al.

    Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2203023.

    Publication Type: Journal Article; Research Support, Non-U.S. Gov't

    Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE

    HTML Full Text PDF Full Text
    Save to List
  2. 2

    Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.

    Authors: Stuart ASV Virta M Williams K et al.

    Source: The Journal of infectious diseases [J Infect Dis] 2022 Dec 28; Vol. 227 (1), pp. 71-82.

    Publication Type: Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

    Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE

    HTML Full Text PDF Full Text
    Save to List
  3. 3

    Roles and responsibilities of participants, researchers, and the media in the communication of vaccine trials: Experience from the United Kingdom's first COVID-19 vaccine trial.

    Authors: Patrick-Smith M Emary K Hodgson SH et al.

    Source: Vaccine [Vaccine] 2024 Dec 02; Vol. 42 (26), pp. 126391. Date of Electronic Publication: 2024 Oct 01.

    Publication Type: Journal Article

    Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE

    Save to List
  4. 4

    Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

    Authors: Shaw RH Greenland M Stuart ASV et al.

    Corporate Authors: Shaw RH Greenland M Stuart ASV et al.

    Source: The Journal of infection [J Infect] 2023 Jun; Vol. 86 (6), pp. 574-583. Date of Electronic Publication: 2023 Apr 06.

    Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't

    Journal Info: Publisher: W.B. Saunders Country of Publication: England NLM ID: 7908424 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2742 (Electronic) Linking ISSN: 01634453 NLM ISO Abbreviation: J Infect Subsets: MEDLINE

    Save to List
  5. 5

    Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.

    Authors: Shaw RH Liu X Stuart ASV et al.

    Corporate Authors: Shaw RH Liu X Stuart ASV et al.

    Source: The Lancet. Respiratory medicine [Lancet Respir Med] 2022 Nov; Vol. 10 (11), pp. 1049-1060. Date of Electronic Publication: 2022 Jun 09.

    Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't

    Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101605555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2619 (Electronic) Linking ISSN: 22132600 NLM ISO Abbreviation: Lancet Respir Med Subsets: MEDLINE

    Save to List
  6. 6

    Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.

    Authors: Stuart ASV Shaw RH Liu X et al.

    Corporate Authors: Stuart ASV Shaw RH Liu X et al.

    Source: Lancet (London, England) [Lancet] 2022 Jan 01; Vol. 399 (10319), pp. 36-49. Date of Electronic Publication: 2021 Dec 06.

    Publication Type: Clinical Trial, Phase II; Equivalence Trial; Journal Article; Randomized Controlled Trial

    Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

    Save to List
  7. 7

    Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

    Authors: Liu X Shaw RH Stuart ASV et al.

    Corporate Authors: Liu X Shaw RH Stuart ASV et al.

    Source: Lancet (London, England) [Lancet] 2021 Sep 04; Vol. 398 (10303), pp. 856-869. Date of Electronic Publication: 2021 Aug 06.

    Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

    Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

    Save to List

Search Tools: